Thyroid Tablets Recalled Nationwide Over Superpotency Risk

Vitruvias Therapeutics Inc. is voluntarily recalling one lot of Thyroid Tablets, USP 30 mg nationwide because testing confirmed the pills may be "superpotent" — stronger than the label says.

The FDA published the recall notice on Aug. 24. The recall goes all the way down to the consumer level, meaning the pills may already be in medicine cabinets.

Check Your Bottle

The affected product is labeled "Thyroid Tablets, USP" 30 mg.

Lot number: 504950. National Drug Code: 69680-166-00. Expiration date: Sept. 30, 2026.

The lot covered 3,655 units, of which 1,955 were distributed to patients across the country between Jan. 31, 2025 and Sept. 30, 2025.

What To Do Today

Do not stop taking the medication on your own. The FDA notice says patients on the recalled lot should not discontinue use without first contacting their health care provider for guidance or a replacement prescription.

Call your doctor if you have had any problems that may be related to the drug.

Questions go to Vitruvias Therapeutics at safety@vitruvias.com or (256) 239-9373 during normal business hours. Adverse reactions can also be reported to the FDA's MedWatch program.

The Risk

Too much thyroid hormone can push patients into hyperthyroidism — an overactive thyroid. The FDA lists possible symptoms including weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate and abnormal heart rhythms.

Vitruvias said elderly people, pregnant women and infants face greater risk, especially after prolonged exposure. In older adults, excess thyroid hormone has been linked to heart-related harm. Overtreatment in pregnancy can raise the risk of premature delivery and low birth weight, the company said, and overtreatment in infants can affect growth and development.